Last updated: July 23, 2026
Tris Pharma Inc. v. Actavis Elizabeth LLC (1:16-cv-00603): Litigation Summary, Timeline, and Patent/Generic Risk Analysis
Tris Pharma Inc. v. Actavis Elizabeth LLC, No. 1:16-cv-00603 is a U.S. patent infringement case tied to an Abbreviated New Drug Application (ANDA) generic challenge filed by Actavis against a Tris Pharma product. The docket number indicates a Hatch-Waxman framework, but the case record required to summarize the asserted patents, claim construction, dispositive motions, and final judgment is not present in the prompt. Under the governing constraints, a complete, accurate litigation summary cannot be produced without those case-specific details.
What patents were asserted in Tris Pharma v. Actavis Elizabeth LLC 1:16-cv-00603?
Answer: Not provided in the available information.
What is needed to identify the asserted patents
- Patent numbers listed in the complaint and Amended Complaint
- Claims asserted and the statutory basis (35 U.S.C. § 271(e)(2)(A) and (B))
- Whether the case was framed as Paragraph IV, Paragraph III, or another Hatch-Waxman posture
When was the Paragraph IV (ANDA) dispute filed for Tris Pharma v. Actavis (1:16-cv-00603)?
Answer: Not provided in the available information.
Timing elements typically tracked in Hatch-Waxman litigation
- ANDA filing date and Paragraph IV notice date
- Complaint filing date and service
- Any amendments tied to updated certifications or sales assumptions
How did claim construction shape the Tris Pharma v. Actavis Elizabeth LLC outcome?
Answer: Not provided in the available information.
Key claim-stage events to check in the docket
- Markman hearing date(s)
- Claim terms construed and their final constructions
- Summary judgment targets linked to those constructions
What were the main defenses Actavis Elizabeth LLC raised in Tris Pharma v. Actavis (1:16-cv-00603)?
Answer: Not provided in the available information.
Common Hatch-Waxman defenses (not confirmed here)
- Non-infringement of asserted claims under the ANDA label and proposed manufacturing
- Invalidity for anticipation, obviousness, lack of enablement, or indefiniteness
- Prosecution history estoppel or prior art rejections impacting claim scope
What was the final litigation disposition in 1:16-cv-00603 (settlement, dismissal, or judgment)?
Answer: Not provided in the available information.
Disposition artifacts that determine commercial impact
- Final judgment date
- Whether a consent judgment or dismissal followed settlement
- Whether there was an order staying the case pending related proceedings
Did Tris Pharma and Actavis Elizabeth LLC enter a settlement agreement, and what did it cover?
Answer: Not provided in the available information.
What settlement terms usually include (not confirmed here)
- Nonsale/nonsublicense covenants
- Launch dates or delayed entry windows
- Carve-outs for design-arounds and updated formulations
- Stated “permitted commercial activities” tied to regulatory milestones
How strong is the patent estate that Tris Pharma asserted against Actavis in 1:16-cv-00603?
Answer: Not provided in the available information.
Patent strength is driven by docket-record facts
- Asserted claim scope and whether dependent claims survived
- Validity rulings, if any, from the district court
- PTAB outcomes (if reexamination or IPR estoppel issues appeared)
What generic entry risks existed for Actavis Elizabeth LLC after (or during) 1:16-cv-00603?
Answer: Not provided in the available information.
Risk drivers typically visible in the record
- Court injunction scope if infringement was found
- Whether design-around efforts were pleaded
- Whether non-infringement or invalidity was resolved on dispositive motion
Which FDA ANDA and Orange Book listings were implicated in Tris Pharma v. Actavis Elizabeth LLC?
Answer: Not provided in the available information.
What to map from the litigation to FDA records
- The ANDA number and proposed product
- The Orange Book listed patents for the reference listed drug (RLD)
- The certification(s) that triggered the lawsuit
How does Tris Pharma’s litigation strategy in 1:16-cv-00603 compare with other Tris Pharma ANDA suits?
Answer: Not provided in the available information.
Comparative factors that require case-identifying details
- Pattern of asserted patents (core compound vs. formulation vs. method-of-use)
- Frequency of settlement vs. trial
- Venue and judge-level tendencies
- Use of stipulations tied to label carve-outs
Key Takeaways
- A litigation summary for Tris Pharma Inc. v. Actavis Elizabeth LLC (1:16-cv-00603) cannot be completed with the required precision because the prompt does not include the docket record content needed to identify asserted patents, procedural milestones, claim constructions, and final disposition.
- The case appears to be a Hatch-Waxman ANDA-linked dispute based on the parties and docket classification, but the specific Hatch-Waxman posture and patent targets are not provided.
FAQs
- What is the case caption scope for 1:16-cv-00603 and who are the named inventors and patent owners?
- Which asserted claims and patent numbers were listed in Tris Pharma’s complaint in 1:16-cv-00603?
- Did the court issue a Markman order in 1:16-cv-00603, and what claim terms were construed?
- Was there a settlement that delayed FDA approval or entry for Actavis’s ANDA?
- Which Orange Book patents correspond to the asserted patents in Tris Pharma v. Actavis?
References
- Court docket: Tris Pharma Inc. v. Actavis Elizabeth LLC, No. 1:16-cv-00603 (U.S. District Court docket record).
